These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22728512)

  • 1. Melanuria in the diagnosis of metastatic melanoma.
    Takeda K; Kenzaka T; Kuroki S; Kajii E
    Intern Med; 2012; 51(12):1649. PubMed ID: 22728512
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver Metastatic Melanoma: a Unique Case with Normal Alkaline Phosphatase and Melanuria.
    Nguyen BX; Petros VS; Aronson JF; Sonstein LK
    J Gastrointest Cancer; 2019 Sep; 50(3):621-624. PubMed ID: 29532312
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
    Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
    Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved HPLC determination of 5-S-cysteinyldopa in serum.
    Wakamatsu K; Ito S
    Clin Chem; 1994 Mar; 40(3):495-6. PubMed ID: 8131290
    [No Abstract]   [Full Text] [Related]  

  • 6. Neural network approach to detection of metastatic melanoma from chromatographic analysis of urine.
    Cohen ME; Hudson DL; Banda PW; Blois MS
    Proc Annu Symp Comput Appl Med Care; 1991; ():295-9. PubMed ID: 1807608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sudden onset of melanuria in a patient with metastatic melanoma and toxic epidermal necrolysis.
    Saghari S; Bakshandeh H; Kerdel F
    Int J Dermatol; 2002 Feb; 41(2):116-8. PubMed ID: 11982652
    [No Abstract]   [Full Text] [Related]  

  • 8. Trichochromes in the urine of melanoma patients.
    Agrup G; Lindbladh C; Prota G; Rorsman H; Rosengren AM; Rosengren E
    J Invest Dermatol; 1978 Feb; 70(2):90-1. PubMed ID: 621413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
    Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
    J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diffuse brown discoloration of skin, mucosa and urine].
    Hallermann C; Schulze HJ
    Hautarzt; 2011 Jan; 62(1):51-3. PubMed ID: 21181099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
    Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
    Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diffuse melanosis in metastatic malignant melanoma with melanuria].
    Moragón M; Pascual R; Ferriz P; Carbonell MA; Ribón F
    An Med Interna; 1990 Jul; 7(7):367-9. PubMed ID: 2103251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
    Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T
    Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data processing of urine chromatograms for the clinical management of melanoma.
    Banda PW; Tuttle MS; Selmer LE; Thatachari YT; Sherry AE; Blois MS
    Comput Biomed Res; 1980 Dec; 13(6):549-66. PubMed ID: 6780261
    [No Abstract]   [Full Text] [Related]  

  • 15. Signet ring cell melanoma, Brenner sign, and elevated vascular endothelial growth factor.
    Russo JJ; Barr KL; Scanlan LZ; Chapman-Fredricks J; Herrera L; Dinges MM; Vincek V
    J Am Acad Dermatol; 2011 Aug; 65(2):444-446. PubMed ID: 21763580
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute kidney injury in a patient with melanuria, diffuse melanosis, and metastatic malignant melanoma.
    Gambichler T; Stücker M; Kerner K; Weiner S; Waldherr R; Altmeyer P; Kreuter A
    Am J Clin Dermatol; 2008; 9(4):267-70. PubMed ID: 18572978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
    Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
    J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-S-cysteinyldopa in urine and tumors.
    Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
    J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma.
    Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U
    Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression.
    Wakamatsu K; Ito S; Horikoshi T
    Melanoma Res; 1991; 1(2):141-7. PubMed ID: 1823626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.